LLVK TFA is a selective IkappaB phosphorylation inhibitor. LLVK TFA reduces LPS-induced pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha). LLVK TFA is promising for research of inflammatory bowel disease and rheumatoid arthritis[1].
Molecular Weight:
585.66
Purity:
99.50
Formula:
C25H46F3N5O7
Target:
IKK,NF-kappaB
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
